F-Prime Capital

Total investments

458

Average round size

44M

Portfolio companies

254

Rounds per year

5.87

Lead investments

26

Follow on index

0.44

Exits

63

Stages of investment
SeedEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareFinancial ServicesInformation TechnologyHealth CareSaaSMedical DeviceMedicalPharmaceuticalTherapeutics

Investments analytics

Analytics

Total investments
458
Lead investments
26
Exits
63
Rounds per year
5.87
Follow on index
0.44
Investments by industry
  • Health Care (224)
  • Biotechnology (191)
  • Medical (110)
  • Software (84)
  • Therapeutics (82)
  • Show 185 more
Investments by region
  • United States (347)
  • United Kingdom (29)
  • China (36)
  • India (14)
  • Canada (6)
  • Show 9 more
Peak activity year
2021
Number of Unicorns
5
Number of Decacorns
6
Number of Minotaurs
5

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
158M
Group Appearance index
0.93
Avg. company exit year
7
Avg. multiplicator
2.09
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Amber Therapeutics 10 Jun 2024 Biotechnology, Therapeutics Early Stage Venture 109M England, London, United Kingdom
OWL 19 Mar 2024 Early Stage Venture 157M Nordrhein-Westfalen, Bielefeld, Germany
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.